Swiss drugmaker Novartis has agreed to acquire Chinook Therapeutics, a US clinical-stage biopharma, for $3.5 billion.
Chinook has two late-stage drugs in development to treat Immunoglobulin A Nephropathy (IgAN), a rare and progressive kidney disease that mostly affects young adults and currently lacks targeted treatment options.
The therapies are Atrasentan, an oral endothelin A receptor antagonist (ERA) and Zigakibart, a monoclonal antibody. Atrasentan is currently in Phase 3 development for IgAN and has shown significant reductions in proteinuria. Atrasentan is also in early-stage development for other rare kidney diseases. A phase 3 trial for Zigakibart in IgAN is expected to start in Q3 2023.
Novartis said Chinook has deep expertise in modeling and understanding kidney disease and a promising early pipeline to address a number of severe renal conditions.
Both companies’ boards have unanimously approved the deal, which is expected to close in the second half of 2023.
Earlier this month, Novartis paid $87.5 million for Avrobio’s investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis, a rare genetic disease where amino acid cystine builds up in the body’s tissues and organs.
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.